Paroxysmal attack

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

Retrieved on: 
Monday, April 1, 2024
FACC, Weill Cornell Medicine, Professor, Safety, NewYork-Presbyterian Hospital, Paroxysmal attack, Paroxysmal supraventricular tachycardia, Efficacy, RAPID, American College, Sinus rhythm, Hospital, Division, Signs and symptoms, Conversion, Pharmaceutical industry

MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at two upcoming cardiology conferences this month.

Key Points: 
  • MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at two upcoming cardiology conferences this month.
  • The company will deliver oral and poster presentations at the American College of Cardiology annual meeting (ACC24) , to be held April 6-8th in Atlanta, Georgia, and a poster presentation at the annual meeting of the European Heart Rhythm Association (EHRA) , to be held April 7-9th in Berlin, Germany.
  • The presentations will be available following the embargo at https://MilestonePharma.com .
  • Multi-Center, Open-Label Study of the Efficacy and Safety of Etripamil Nasal Spray Self-Administered For Multiple Episodes of Symptomatic Supraventricular Tachycardia Without Supervision (Phase 3, NODE-303)
    James Ip, M.D., Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital
    Symptom-prompted, Self-administered Intranasal Etripamil for Termination of Paroxysmal Supraventricular Tachycardia in the RAPID Study: Relationship Among Etripamil-Induced Reduction in Tachycardia Rates, Conversion to Sinus Rhythm, and Improvement in Patient Symptoms
    James Ip, M.D., Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital
    Characterising paroxysmal supraventricular tachycardia episodes by patient-perceived episode duration, symptoms, and severity: longitudinal patient-reported outcomes
    David Bharucha, M.D., Ph.D., FACC, Chief Medical Officer of Milestone Pharmaceuticals, Inc.

Human medicines European public assessment report (EPAR): Epysqli, Date of authorisation: 26/05/2023, Revision: 1, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, Protein, Risk, Immune system, Infection, ATC, Neisseria meningitidis, Paroxysmal nocturnal hemoglobinuria, Bleeding, PNH, Disease, Headache, Pharmacist, LDH, Language, Vaccination, Medicine, Blood, Laboratory, European Medicines Agency, C5, Select, Cell, Safety, Hemolysis, Bacteria, Anatomy, Paroxysmal attack, Anemia, Hematology, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Epysqli, Date of authorisation: 26/05/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Epysqli, Date of authorisation: 26/05/2023, Revision: 1, Status: Authorised

First Look at Data on Biosense Webster's Investigational Pulsed Field Ablation Platform Presented at AF Symposium 2023

Retrieved on: 
Saturday, February 4, 2023
PFA, Data monitoring committee, Paroxysmal attack, PVI, President of the European Union, Trial of the century, Atrial fibrillation, Pulmonary vein stenosis, Vein, PF, Safety, Leona, Johnson & Johnson, Patient, Icahn School of Medicine at Mount Sinai, Mount, Clinical trial, Recurrence, Kansas Day, Reflex, Risk, Medical Affairs Bureau, Cardiac electrophysiology, Arrhythmia, IRE, Catheter, I-40, Mount Sinai Health System, Mount Sinai Hospital (Manhattan), MD, Medical imaging, Medical device, Pharmaceutical industry, Ventricular fibrillation, Medicine, Electrophysiology

IRVINE, Calif., Feb. 3, 2023 /PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i announced that positive results from the inspIRE company-sponsored clinical trial were presented as a late breaker, titled "Paroxysmal AF Ablation Using a Variable-Loop Pulsed Field Ablation Catheter Integrated with a 3D Mapping System: One-Year Outcomes from inspIRE," at the 28th Annual International AF Symposium.

Key Points: 
  • In addition to being presented as an AF Symposium late breaker, the data will be simultaneously published in Circulation: Arrhythmia and Electrophysiology.
  • Pulsed Field Ablation (PFA) represents a new approach to treating atrial fibrillation (AFib), utilizing a controlled electric field to ablate cardiac tissue through a process called irreversible electroporation (IRE).
  • In wave II, an independent Data Monitoring Committee declared early success after 186-patient enrollment and 60 patients completing 12-month follow-up.
  • VARIPULSE™ is a steerable, multielectrode, catheter enabling cardiac electrophysiological mapping and ablation functionalities through the investigational TRUPULSE™ Generator.

Biosense Webster, Inc. to Highlight Latest Innovations at AF Symposium 2023 Showcasing Breadth of Cardiac Rhythm Portfolio

Retrieved on: 
Monday, January 23, 2023
Rhea, Safety, VisionMap A3 Digital Mapping System, Multicenter trial, Ventricular fibrillation, Medical Affairs Bureau, Diagnosis, President of the European Union, Atrial fibrillation, Arrhythmia, PFA, Treatment, FDA, Catheter, Catheter ablation, Johnson & Johnson, Physician, RFA, Patient, Clinical trial, PVI, Electrophysiology, Paroxysmal attack, Radiofrequency ablation, Science, Pharmaceutical industry, Medical device, Medical imaging

IRVINE, Calif., Jan. 23, 2023 /PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i announced that data from five company-sponsored studies, including two late breakers, will be presented at the 28th Annual International AF Symposium in Boston from February 2–4. The studies span innovations in radiofrequency ablation (RFA) and pulsed field ablation (PFA) and are part of Biosense Webster, Inc.'s long-standing commitment to advancing electrophysiology innovation.

Key Points: 
  • The studies span innovations in radiofrequency ablation (RFA) and pulsed field ablation (PFA) and are part of Biosense Webster, Inc.'s long-standing commitment to advancing electrophysiology innovation.
  • "As a long-standing leader in this space, we are committed to harnessing the latest science and technology and working in collaboration with physicians to deliver best-in-class solutions."
  • Data from five Biosense Webster, Inc.-sponsored studies will be presented, spanning key topics in electrophysiology.
  • For more information about Biosense Webster Inc.'s presence at AF Symposium and the conference schedule, please visit https://www.afsymposium.com/2023-program .

Milestone Pharmaceuticals to Host Virtual Commercial Deep-Dive Event on Etripamil for PSVT

Retrieved on: 
Tuesday, November 29, 2022
COVID-19, Supraventricular tachycardia, Conference call, Dizziness, Adenosine, Revera, Syncope, Palpitations, Calcium channel, Perspiration, Pain, Safety, Baozou Big News Events, Patient, Fatigue, Pandemic, Anxiety, Paroxysmal attack, Paroxysmal supraventricular tachycardia, Webcast, Annual report, NDA, RAPID, Risk, PSVT, Atrial fibrillation, News, Clinical trial, SVT, Form 10-K, Lightheadedness, Pharmaceutical industry, Milestone, Conference

ET

Key Points: 
  • ET
    MONTREALandCHARLOTTE, N.C., Nov. 29, 2022 /PRNewswire/ --Milestone Pharmaceuticals Inc.(Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of the Company's management team will host a virtual commercial deep-dive event on Tuesday, December 6, 2022 at 1:00 p.m.
  • The event will focus on the commercial opportunity for etripamil, the Company's lead investigational product, for the treatment of patients with paroxysmal supraventricular tachycardia (PSVT).
  • To access a live or recorded webcast of the event and accompanying slides, please visit the News & Events section of Milestone's website at www.milestonepharma.com .
  • Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines.

ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial

Retrieved on: 
Wednesday, August 3, 2022
FDA, Diabetes, Health, Pharmaceutical, Clinical Trials, Human, PNH, USD, US FDA, Paroxysmal nocturnal hemoglobinuria, Standard of care, Fatigue, Metabolic syndrome, Degenerative disease, Patient, Paroxysmal attack, Time-invariant system, Seasonal adjustment, US, Anemia, Membrane protein, KRW, Therapy, Diabetic retinopathy, Immune system, Dream, Clinical trial, Growth, Pharmaceutical industry, Vaccine

ImmunAbs Inc. ( www.immunabs.com ) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States.

Key Points: 
  • ImmunAbs Inc. ( www.immunabs.com ) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States.
  • ImmunAbs new complement therapeutic IM-101 targets the safest and most potent component of the complement system, complement C5.
  • ImmunAbs will initiate a phase 2a clinical trial in the United States in 2024.
  • Currently, ImmunAbs has several antibody therapeutics in global standard development for autoimmune diseases, diabetic retinopathy, and metabolic syndrome.

Study Finds 89% of Patients Treated for Persistent Atrial Fibrillation Using Abbott's Ablation Device Remain Symptom-Free for at Least 15 Months

Retrieved on: 
Friday, April 29, 2022
Life, Radio, NYSE, Heart failure, Arrhythmia, Freedom, Pressure, Patient, Atrial fibrillation, Atrial flutter, Șaeș, Stroke, AAD, Paroxysmal attack, Catheter, Cell, Quality of life, Class, Tachycardia, Adviser, Parenteral nutrition, Heart, Heart Rhythm Society, Physician, Recurrence, Safety, Medical imaging, Pharmaceutical industry, Medical device, Ventricular fibrillation

Millions of Americans are affected by abnormal heart rhythms, known as arrhythmias, caused by breakdowns in the electrical pathways of the heart.

Key Points: 
  • Millions of Americans are affected by abnormal heart rhythms, known as arrhythmias, caused by breakdowns in the electrical pathways of the heart.
  • Patients were evaluated for 15 months following the cardiac ablation procedure for safety, efficacy, and quality of life measures.
  • The rate of serious adverse events was 3.1%, which is consistent with other studies in the persistent AFib population.
  • Similarly, the patients' average annual overall cardiovascular-related health care utilization decreased by 53% in the 15 months following ablation compared to pre-ablation utilization.

Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of PSVT

Retrieved on: 
Thursday, April 14, 2022
Annual report, Pain, U.S. Securities and Exchange Commission, Conference call, COVID-19, Atrial fibrillation, MBA, Twitter, Anxiety, Private Securities Litigation Reform Act, Lightheadedness, RAPID, News, Risk, Patient, Paroxysmal attack, Duke University School of Medicine, Form 10-K, Paroxysmal supraventricular tachycardia, Syncope, Conference, Review, FHRS, KOL, Company, Nasdaq, Dizziness, Webcast, Forward-looking statement, Perspiration, GA, Research, Safety, Education, Adenosine, Calcium channel, Assistant, Revera, Pandemic, Palpitations, Fatigue, PSVT, Pharmaceutical industry, MD, Milestone

ET

Key Points: 
  • ET
    MONTREALandCHARLOTTE, N.C., April 14, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc.(Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the Company will host a virtual Key Opinion Leader (KOL) event on Thursday, April 21, 2022 at 1:00 p.m.
  • The event will focus on etripamil, the Company's lead investigational product, for the treatment of patients with paroxysmal supraventricular tachycardia (PSVT).
  • Certain intravenous medications, including adenosine, beta-blockers and calcium channel blockers, have long been used for the acute treatment of PSVT.
  • Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines.

First Patient Dosed in CAN106 Phase 1b/2 Trial for Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in China

Retrieved on: 
Monday, March 28, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Kidney, Cell, Thrombosis, Heart, MPS II, University of Massachusetts Medical School, University, MAC, Death, 2-Bromo-LSD, Glioblastoma, Degenerative disease, Patient, Pulmonary hypertension, GBM, Peking Union Medical College Hospital, Research, WuXi Biologics, Incidence, C3a, PNH, Hemolysis, PHN, Paroxysmal nocturnal hemoglobinuria, Hunter syndrome, Administration, CEO, C3, Anemia, MPS, C5, Safety, C5a, Steroid, Diagnosis, Glycogen storage disease, C3b, University of Massachusetts, Disorder, CH50, Complement component 5, Lists of diseases, Paroxysmal attack, Medicine, Fatigue, Protein, Spiroplasma mirum, Ravulizumab, Haemophilia, Pharmaceutical industry, Vaccine, Fine chemical, Hematology, CAN106, PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH), CANBRIDGE PHARMACEUTICALS INC.

CAN106 was previously shown to be safe and well-tolerated, with dose-dependent and linear pharmacokinetic exposure, in a study of healthy volunteers in Singapore.

Key Points: 
  • CAN106 was previously shown to be safe and well-tolerated, with dose-dependent and linear pharmacokinetic exposure, in a study of healthy volunteers in Singapore.
  • Based on these results, Chinas National Medical Products Administration approved the CAN106 Phase 1b/2 trial for the treatment of patients with PNH.
  • CAN106 is a novel, long-acting recombinant human monoclonal antibody that binds to and neutralizes C5, a key component of the complement system.
  • Paroxysmal nocturnal hemoglobinuria (PNH) belongs to a group of fatal and rare disorders that occur when the complement system is dysregulated.

CANbridge Reports Positive Top-Line CAN106 Phase 1 Data

Retrieved on: 
Monday, February 7, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, PNH, Disorder, MPS II, Single, C5, Immune system, IND, MPS, Ravulizumab, Investigational New Drug, Safety, Anemia, 2-Bromo-LSD, Glioblastoma, Steroid, Hemolysis, Glycogen storage disease, Cell, Blood, SAD, WuXi Biologics, Complement component 5, Paroxysmal nocturnal hemoglobinuria, Research, C3, Șaeș, Haematopoietic system, Haemophilia, C3b, Pulmonary hypertension, Incidence, Paroxysmal attack, Patient, Kidney, Heart, University of Massachusetts, Diagnosis, Hunter syndrome, Protein, University, PHN, PK, GBM, Thrombosis, Lists of diseases, CEO, C5a, Spiroplasma mirum, Death, C3a, MAC, CH50, PD, University of Massachusetts Medical School, Partnership, Degenerative disease, Fatigue, Vaccine, Pharmaceutical industry, Palladium, Fine chemical, Pharmacokinetics, the Study, CAN106, Paroxysmal Nocturnal Hemoglobinuria (PNH), CANbridge Pharmaceuticals Inc., THE STUDY, CAN106, PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH), CANBRIDGE PHARMACEUTICALS INC.

CAN106 was shown to be safe and well-tolerated with mostly mild or moderate adverse events and no drug-related serious adverse events (SAEs).

Key Points: 
  • CAN106 was shown to be safe and well-tolerated with mostly mild or moderate adverse events and no drug-related serious adverse events (SAEs).
  • CAN106 showed dose-dependent and linear pharmacokinetic exposure with low inter-subject variability and a terminal elimination half-life of approximately 32 days.
  • These results suggest complete functional blockade of terminal complement activity, and importantly, provide the first human data validating CAN106 as a potential treatment for complement-mediated diseases.
  • The objectives were to assess the safety and tolerability of single escalating doses of CAN106, to characterize the PK and PD profile of CAN106, and to evaluate the immunogenicity of CAN106.